Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.655 USD | -3.59% | -10.28% | -25.51% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.51% | 228M | |
+10.28% | 226B | |
+14.15% | 198B | |
+18.34% | 142B | |
+29.29% | 111B | |
+2.09% | 65.26B | |
+14.59% | 54.36B | |
+6.68% | 50.94B | |
+8.41% | 44.8B | |
+3.07% | 36.8B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16